# Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

> **NCT00529451** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1613 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT00529451
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 1613 (ACTUAL)
- **Last updated:** 2011-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529451, "Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00529451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*